Advances in mRNA vaccine therapy for breast cancer research
Discover Oncology,
Год журнала:
2025,
Номер
16(1)
Опубликована: Май 6, 2025
Breast
cancer
represents
the
most
prevalent
among
women
globally,
constituting
approximately
30%
of
newly
diagnosed
female
malignancies
and
serving
as
second
leading
cause
cancer-related
mortality,
accounting
for
11.6%
deaths.
Despite
notable
advancements
in
survival
rates
quality
life
breast
patients
over
recent
decades-achieved
through
interventions
such
surgery,
chemotherapy,
radiotherapy,
endocrine
therapy-there
remains
an
urgent
need
novel
therapeutic
strategies.
This
necessity
arises
from
challenges
associated
with
recurrence,
metastasis,
drug
resistance.
The
COVID-19
pandemic
has
accelerated
development
Messenger
RNA
(mRNA)
vaccines
at
unprecedented
pace,
a
form
precision
immunotherapy,
mRNA
are
increasingly
being
recognized
their
potential
treatment.
efficiently
produce
antigens
within
cytoplasm,
specifically
activating
immune
system
to
target
tumor
cells
while
minimizing
risk
T-cell
tolerance.
Therefore,
have
emerged
promising
approach
immunotherapy.
review
systematically
examines
principles,
mechanisms,
advantages,
key
targets,
progress
vaccine
therapy
cancer.
Furthermore,
it
discusses
current
suggests
directions
future
research.
Язык: Английский
Novel treatment approaches utilizing antibody-drug conjugates in breast cancer
npj Breast Cancer,
Год журнала:
2025,
Номер
11(1)
Опубликована: Май 13, 2025
Antibody-drug
conjugates
(ADCs)
are
rapidly
changing
the
way
we
treat
patients
with
breast
cancer.
Despite
this
progress,
many
unanswered
questions
remain
regarding
sequencing
of
different
ADCs
similar
payloads,
optimal
combinations,
drug
design
strategies
to
limit
off-target
toxicities,
biomarkers
define
antigen
positivity,
and
use
in
neoadjuvant
adjuvant
settings.
In
review,
summarize
novel
ADC
approaches
cancer
treatment,
including
potential
improvements
linkers,
targets,
delivery.
We
also
evaluate
combine
other
agents,
such
as
targeted
drugs
immune
checkpoint
inhibitors.
To
improve
patient
selection,
development
quantitative
is
reviewed,
HER2
mRNA,
immunofluorescence-based
assays,
mass
spectrometry,
liquid
biopsies,
digital
pathology,
molecular
imaging-based
approaches.
Lastly,
incorporate
into
early-stage
setting,
evaluating
currently
published
ongoing
clinical
trials.
This
review
highlights
for
shift
treatment
paradigm
both
advanced
further
demonstrate
complexity
challenges
improving
enhance
targeting
tumor
vulnerabilities
while
limiting
toxicity
through
rationale
therapeutic
window,
linker
technology,
payload
variability
continue
outcomes
Язык: Английский